Novavax's Nuvaxovid COVID-19 Vaccine Receives Full FDA Approval for Adults 65+ and High-Risk Individuals Aged 12-64
I'm PortAI, I can summarize articles.
Novavax Inc. has received full FDA approval for its Nuvaxovid COVID-19 vaccine, which is now licensed for adults 65+ and high-risk individuals aged 12-64. This approval is based on Phase 3 clinical trial data demonstrating safety and effectiveness. Nuvaxovid is the only non-mRNA protein-based COVID-19 vaccine in the U.S. Sanofi will handle its commercialization and distribution, enhancing access for those seeking vaccination.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments